

Supplemental Table S2: Search strategies and inclusion/exclusion criteria

conducted on 12/7/17

<p>Embase <1974 to 2017 July 11></p> <ol style="list-style-type: none">1 xenograft/ (40270)2 (xenograft\$ or explant\$ or explants).ti,ab. (123979)3 1 or 2 (133527)4 ((patient\$ or human\$) adj2 derived).ti,ab. (44918)5 3 and 4 (5520)6 conference\$.pt. (3369534)7 5 not 6 (2608)
<p>MEDLINE(R) <1946 to June Week 5 2017></p> <ol style="list-style-type: none">1 Heterografts/ (3905)2 (xenograft\$ or explant\$ or explants).ti,ab. (79098)3 1 or 2 (81226)4 ((patient\$ or human\$) adj2 derived).ti,ab. (28090)5 3 and 4 (1964)
<p>MEDLINE(R) Epub Ahead of Print <July 11, 2017>, MEDLINE(R) In-Process & Other Non-Indexed Citations <July 11, 2017>, MEDLINE(R) Daily Update <July 10, 2017></p> <ol style="list-style-type: none">1 Heterografts/ (12)2 (xenograft\$ or explant\$ or explants).ti,ab. (10387)3 1 or 2 (10392)4 ((patient\$ or human\$) adj2 derived).ti,ab. (4102)5 3 and 4 (742)

Inclusion / Exclusion criteria

	Include	Exclude
Population	Murine xenografts derived from human carcinoma tissues of breast, colon, lung or prostate (fragments or freshly isolated primary cells at ≤ 3 passages)	<p>Metastatic tumours</p> <p>Lymphoma, leukaemia, sarcomas, melanoma, brain tumours (glioma, medullablastoma etc.), squamous cell carcinoma, cystic carcinoma, teratoma</p> <p>Xenografts derived from cell lines or primary samples ≥ 4 passages (or unclear passage) or genetically manipulated cells</p> <p>Rat, canine xenografts</p>
Outcomes	<p>Validation:</p> <ol style="list-style-type: none"> 1. Xenograft and tumour histology 2. Confirmation of human tumour cells (exclusion of mouse cells and normal human cells for primary outgrowth only) 3. Confirmation of tissue type 4. Confirmation of cellular type 5. Confirmation of tumour markers 6. Confirmation of lymphoma or EBV (T cell, B cell, NK cell) 	
Outcomes For extraction but not inclusion	<ol style="list-style-type: none"> 7. Engraftment rate (primary outgrowth); percentage of biopsies which develop xenografts 8. Latency 9. Percentage of biopsies resulting in stable lines 10. Percentage of biopsies resulting in lymphomas 11. Clinical characteristics of patient tumour tissue 	